Filing Details

Accession Number:
0001127602-22-018935
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-07-06 16:17:41
Reporting Period:
2022-07-01
Accepted Time:
2022-07-06 16:17:41
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1145197 Insulet Corp PODD Surgical & Medical Instruments & Apparatus (3841) 043523891
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1631895 Shacey Petrovic C/O Insulet Corporation
100 Nagog Park
Acton MA 01720
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-07-01 7,070 $29.26 20,765 No 4 M Direct
Common Stock Acquisiton 2022-07-01 7,930 $46.22 28,695 No 4 M Direct
Common Stock Disposition 2022-07-01 15,000 $222.90 13,695 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2022-07-01 7,070 $0.00 7,070 $29.26
Common Stock Employee Stock Option (Right to Buy) Disposition 2022-07-01 7,930 $0.00 7,930 $46.22
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2026-02-24 No 4 M Direct
25,445 2027-02-22 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 61,259 Indirect By NG Trust
Common Stock 26,304 Indirect By SP Trust
Footnotes
  1. The transactions reported in this Form 4 were effected pursuant to an existing Rule 10b5-1 trading plan.
  2. Includes 88 shares acquired under the Insulet Corporation Employee Stock Purchase Plan on May 31, 2022.
  3. The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $214.16 to $226.52. Specifically: 21 shares were sold in the range of $214.16 to $214.26 per share, with a weighted average share price of $214.26; 23 shares were sold at a price $215.19; 400 shares were sold in the range of $216.59 to $217.58 per share, with a weighted average share price of $217.09; 106 shares were sold in the range of $218.83 to $219.81 per share, with a weighted average share price of $218.89; 1,299 shares were sold in the range of $220.09 to $221.02 per share, with a weighted average share price of $220.47; 2,988 shares were sold in the range of $221.21 to $222.18 per share, with a weighted average share price of $221.68; 3,930 shares were sold in the range of $222.27 to $223.27 per share, with a weighted average share price of $222.81; 2,812 shares were sold in the range of $223.35 to $224.34 per share, with a weighted average share price of $223.75; 2,113 shares were sold in the range of $224.37 to $225.33 per share, with a weighted average share price of $224.71 and 1,308 shares were sold in the range of $225.57 to $226.52 per share, with a weighted average share price of $226.03. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
  4. This option is subject to a four-year vesting period with 25% of the total award vesting one year after the grant date and the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters, subject to continued employment.